Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination.
Elisa HabermannLutz GieselmannPinkus Tober-LauJens KlotscheFredrik Nils AlbachAlexander Ten HagenJan ZernickeElvin AhmadovAmanthi Nadira Arumahandi de SilvaLeonie Maria FrommertFlorian KurthLeif-Erik SanderGerd-Rüdiger R BurmesterFlorian KleinRobert BiesenPublished in: RMD open (2022)
Patients pausing MTX after COVID-19 booster showed a similar vaccine response to NIP. Patients who continued MTX demonstrated an impaired response indicating a potentially beneficial second booster vaccination. Our data also suggest that a 1 week MTX break is sufficient if the last administration of MTX occurs 1-3 days before vaccination.
Keyphrases
- coronavirus disease
- sars cov
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- high dose
- prognostic factors
- electronic health record
- randomized controlled trial
- clinical trial
- respiratory syndrome coronavirus
- low dose
- mouse model
- machine learning
- big data
- study protocol